Jpmorgan Chase & CO Evogene Ltd. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.61 - $0.82 $14,921 - $20,058	-24,461 Reduced 62.04%	14,969 $9,000
Q1 2024 May 10, 2024	SELL	$0.7 - $0.98 $17,614 - $24,660	-25,164 Reduced 38.96%	39,430 $29,000
Q4 2023 Feb 12, 2024	BUY	$0.47 - $0.88 $13,787 - $25,815	29,336 Added 83.2%	64,594 $54,000
Q3 2023 Nov 14, 2023	BUY	$0.58 - $1.41 $20,449 - $49,713	35,258 New	35,258 $20,000
Q1 2023 May 11, 2023	SELL	$0.59 - $0.86 $38 - $56	-66 Reduced 48.18%	71 $0
Q4 2022 Feb 13, 2023	BUY	$0.61 - $8.13 $83 - $1,113	137 New	137 $0
Q2 2022 Aug 11, 2022	SELL	$0.75 - $1.33 $3,869 - $6,861	-5,159 Reduced 51.99%	4,765 $4,000
Q1 2022 May 11, 2022	SELL	$1.09 - $1.83 $8,578 - $14,402	-7,870 Reduced 44.23%	9,924 $13,000
Q4 2021 Feb 10, 2022	SELL	$1.63 - $2.83 $257,766 - $447,533	-158,139 Reduced 89.89%	17,794 $29,000
Q3 2021 Nov 12, 2021	BUY	$2.45 - $3.45 $431,035 - $606,968	175,933 New	175,933 $464,000

117K

Ticker EVGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,202,000
Market Cap $61.4M
Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.